uniQure N.V. (QURE)
NASDAQ: QUREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 10:11 AM ET
QURE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.58B
- EPS (TTM)
- -$4.03
- Dividend yield
- None
- 52-week range
- 8.73 – 71.50
- Day range
- 22.33 – 23.00
- Volume / Avg
- 101.33K / 1.97M
- Beta
- —
- Shares outstanding
- 69.37M
52-week range
QURE stock today
On Oct 9, QURE is trading at $22.78, adding $0.24 (1.06%), versus the S&P 500's 0.28% gain. Shares are 68.1% below their 52-week high of $71.50, set on Oct 28, 2025 and 160.9% above the 52-week low of $8.73, in the middle of the past year's range. QURE is down 5.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 62.4%.
uniQure N.V. has posted a net loss over the last twelve months (EPS of -$4.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About uniQure N.V.
Company profileuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Matthew Craig Kapusta CPA
- Headquarters
- Amsterdam
- Employees
- 221
- IPO year
- 2014
- Website
- uniqure.com
Financial highlights
Full financialsIn fiscal 2025, uniQure N.V. generated $16.1 million in revenue, down 40.6% from fiscal 2024, its first annual decline since 2023. uniQure N.V. reported a net loss of $199.0 million, compared with a loss of $239.6 million a year earlier. Gross margin was 89.5% (down from 95.3%) and operating margin -1151.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $16.10M | $27.12M | $15.84M | $106.48M | $524.00M |
| Growth | -40.64% | +71.17% | -85.12% | -79.68% | +1296.82% |
| Net income | $-198.97M | $-239.56M | $-308.48M | $-126.79M | $329.59M |
| EPS (diluted) | $-3.46 | $-4.92 | $-6.47 | $-2.71 | $7.04 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$62.33+173.62%
- Strong buy 1
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q1 2026)
- May 5, 2026
- EPS actual vs est.
- $-0.85 vs —
uniQure N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PAHCPhibro Animal Health Corporation Class A | 38.75 | +3.60% | $1.57B | vs QURE |
| SNDXSyndax Pharmaceuticals Inc. | 17.35 | +2.63% | $1.55B | vs QURE |
| KRSAKorsana Biosciences Inc. | 34.00 | +1.45% | $1.55B | vs QURE |
| STOKStoke Therapeutics Inc. | 24.63 | +2.84% | $1.59B | vs QURE |
| RAREUltragenyx Pharmaceutical Inc. | 15.55 | +1.67% | $1.53B | vs QURE |
| INVAInnoviva Inc. | 21.06 | +0.89% | $1.52B | vs QURE |
| ETONEton Pharmaceuticals Inc. | 56.20 | +2.64% | $1.61B | vs QURE |
| CMPSCOMPASS Pathways Plc American Depository Shares | 11.71 | +2.12% | $1.62B | vs QURE |
Indexes, lists and sector
uniQure N.V. stock FAQ
What is uniQure N.V.'s stock price today?
QURE last traded at $22.78 as of Oct 9, 10:11 AM EDT, up 1.06% on the day. Prices are delayed at least 15 minutes.
Who is uniQure N.V.'s CEO?
Mr. Matthew Craig Kapusta CPA is the chief executive officer of uniQure N.V., which has about 221 employees.
What is the QURE 52-week high?
The 52-week high for QURE is $71.50 and the 52-week low is $8.73. The stock is currently 68.1% below its high.